H. Lundbeck A/S

Industry

  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Vaccines

Other Names/Subsidiaries

  • Abide Therapeutics
  • Alder Biopharmaceuticals
  • Chelsea Therapeutics International
  • Longboard Pharmaceuticals
  • Lundbeck La Jolla Research Center
  • Lundbeck Seattle Biopharmaceuticals
  • Ovation Pharmaceuticals
  • Saegis Pharmaceuticals
See more in Biomedtracker

Latest on H. Lundbeck A/S

Pink Sheet

Don’t Look Back: US FDA AdComm Offers No Flexibility For Rexulti’s Post Hoc Bid In PTSD

 
• By Bridget Silverman

Where talk of regulatory flexibility is common in contested approval decisions, the US Food and Drug Administration’s Psychopharmacology Drugs Advisory Committee emphasized maintaining high and rigoro

Pink Sheet

Otsuka/Lundbeck’s Rexulti PTSD Claim Will Test US FDA AdComm’s Supportive Evidence Flexibility

 
• By Bridget Silverman

Otsuka and H. Lundbeck ’s post hoc bid to elevate a hypothesis-generating Phase II study into a supporting evidentiary role will be a focus of the FDA’s Psychopharmacology Drugs Advisory Committee r

Scrip

Lundbeck Lifted By Leap In Migraine Therapy Sales

 
• By Kevin Grogan

Lundbeck’s transformation under CEO Charl van Zyl continues apace and the CNS-focused Danish drugmaker has raised its full-year guidance after posting a strong set of financials for the first quarter.

In Vivo

How Charl Van Zyl Is Reimagining Lundbeck

 
• By David Wild

Amid an industry-wide scramble to secure growth beyond looming patent cliffs, Denmark’s Lundbeck is undergoing a strategic transformation under CEO Charl van Zyl. Since taking the helm in 2023, van Zy